Critical Survey: Korro Bio (NASDAQ:KRRO) versus Celldex Therapeutics (NASDAQ:CLDX)

Korro Bio (NASDAQ:KRRO) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Korro Bio and Celldex Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1	2	6	3	2.92
Celldex Therapeutics	1	1	11	1	2.86

Korro Bio presently has a consensus price target of $16.50, suggesting a potential upside of 62.40%. Celldex Therapeutics has a consensus price target of $61.92, suggesting a potential upside of 107.17%. Given Celldex Therapeutics’ higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Korro Bio.

Profitability

This table compares Korro Bio and Celldex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Korro Bio	N/A	-114.26%	-68.57%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Volatility and Risk

Korro Bio has a beta of 3.13, indicating that its stock price is 213% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Insider & Institutional Ownership

13.2% of Korro Bio shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Korro Bio and Celldex Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39 million	23.42	-$117.26 million	($10.00)	-1.02
Celldex Therapeutics	$1.54 million	1,524.20	-$258.76 million	($4.35)	-6.87

Korro Bio has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.